Compounders Research Compare

Immunome, Inc.(IMNM)

Biotechnology · Bothell, WA

$19.34-1.83 (-8.64%)

Delayed quote: Oct 6, 2026, 2:25 PM EDT

About Immunome, Inc.

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Bothell, WA

247 employees

www.immunome.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Clay Siegall

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T18:27:03.004Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:27:03.004Z.

Quote observation: 2026-10-06T18:25:10.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,848,811,903
Total debt · period ending 2026-06-30: 4,588,000
Cash · period ending 2026-06-30: 217,706,000
TTM operating income · period ending 2026-06-30: -270,465,000

FMP input reference: 243952859d49b374df7eb324c8bbcd7e4caeb894f26e22f2834818a88b726353

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

IMNM EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

IMNM Competitors' EV/EBIT Ratio

Immunome, Inc.

Current

Market Cap

$1.85B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Astrana Health, Inc.

Market Cap

$1.85B

EV/EBIT Ratio

24.14x

TTM Avg

27.59x

3Y Avg

23.49x

5Y Avg

21.15x

Azenta, Inc.

Market Cap

$1.84B

EV/EBIT Ratio

N/A

TTM Avg

227.18x

3Y Avg

114.14x

5Y Avg

99.57x

Sarepta Therapeutics, Inc.

Market Cap

$1.82B

EV/EBIT Ratio

N/A

TTM Avg

199.19x

3Y Avg

199.19x

5Y Avg

199.19x

Palvella Therapeutics, Inc.

Market Cap

$1.87B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LeMaitre Vascular, Inc.

Market Cap

$1.82B

EV/EBIT Ratio

25.65x

TTM Avg

35.10x

3Y Avg

39.10x

5Y Avg

37.80x

Xencor, Inc.

Market Cap

$1.82B

EV/EBIT Ratio

N/A

TTM Avg

30.48x

3Y Avg

45.80x

5Y Avg

56.24x

Trevi Therapeutics, Inc.

Market Cap

$1.89B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BioLife Solutions, Inc.

Market Cap

$1.89B

EV/EBIT Ratio

251.96x

TTM Avg

240.22x

3Y Avg

240.22x

5Y Avg

240.22x

Novavax, Inc.

Market Cap

$1.81B

EV/EBIT Ratio

N/A

TTM Avg

3.63x

3Y Avg

3.63x

5Y Avg

3.63x

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Immunome, Inc. (IMNM)	$1.85B	N/A	N/A	N/A	N/A
Astrana Health, Inc. (ASTH)vs ›	$1.85B	24.14x	27.59x	23.49x	21.15x
Azenta, Inc. (AZTA)vs ›	$1.84B	N/A	227.18x	114.14x	99.57x
Sarepta Therapeutics, Inc. (SRPT)vs ›	$1.82B	N/A	199.19x	199.19x	199.19x
Palvella Therapeutics, Inc. (PVLA)vs ›	$1.87B	N/A	N/A	N/A	N/A
LeMaitre Vascular, Inc. (LMAT)vs ›	$1.82B	25.65x	35.10x	39.10x	37.80x
Xencor, Inc. (XNCR)vs ›	$1.82B	N/A	30.48x	45.80x	56.24x
Trevi Therapeutics, Inc. (TRVI)vs ›	$1.89B	N/A	N/A	N/A	N/A
BioLife Solutions, Inc. (BLFS)vs ›	$1.89B	251.96x	240.22x	240.22x	240.22x
Novavax, Inc. (NVAX)vs ›	$1.81B	N/A	3.63x	3.63x	3.63x

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics